Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database.

<h4>Background</h4>Elevated inflammatory cytokines in Coronavirus disease 2019 (COVID-19) affect the lungs leading to pneumonitis with a poor prognosis. Tocilizumab, a type of humanized monoclonal antibody antagonizing interleukin-6 receptors, is currently utilized to treat COVID-19. The present stu... View More